AU2007222991A1 - Compositions and methods based on peptide binding profiling - Google Patents

Compositions and methods based on peptide binding profiling Download PDF

Info

Publication number
AU2007222991A1
AU2007222991A1 AU2007222991A AU2007222991A AU2007222991A1 AU 2007222991 A1 AU2007222991 A1 AU 2007222991A1 AU 2007222991 A AU2007222991 A AU 2007222991A AU 2007222991 A AU2007222991 A AU 2007222991A AU 2007222991 A1 AU2007222991 A1 AU 2007222991A1
Authority
AU
Australia
Prior art keywords
lung
colon
renal
melanoma
breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007222991A
Other languages
English (en)
Other versions
AU2007222991A2 (en
AU2007222991A8 (en
Inventor
Wadih Arap
Mikhail Kolonin
Renata Pasqualini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2007222991A1 publication Critical patent/AU2007222991A1/en
Publication of AU2007222991A2 publication Critical patent/AU2007222991A2/en
Publication of AU2007222991A8 publication Critical patent/AU2007222991A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2007222991A 2006-03-09 2007-03-09 Compositions and methods based on peptide binding profiling Abandoned AU2007222991A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78089306P 2006-03-09 2006-03-09
US60/780,893 2006-03-09
PCT/US2007/063736 WO2007104062A2 (en) 2006-03-09 2007-03-09 Compositions and methods based on peptide binding profiling

Publications (3)

Publication Number Publication Date
AU2007222991A1 true AU2007222991A1 (en) 2007-09-13
AU2007222991A2 AU2007222991A2 (en) 2009-03-12
AU2007222991A8 AU2007222991A8 (en) 2011-03-10

Family

ID=38475889

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007222991A Abandoned AU2007222991A1 (en) 2006-03-09 2007-03-09 Compositions and methods based on peptide binding profiling

Country Status (6)

Country Link
US (3) US7781565B2 (https=)
EP (2) EP2338898A1 (https=)
JP (1) JP5167155B2 (https=)
AU (1) AU2007222991A1 (https=)
CA (1) CA2645277A1 (https=)
WO (1) WO2007104062A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9575070B2 (en) * 2001-12-04 2017-02-21 Wayne State University Neoepitope detection of disease using protein arrays
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
CA2655933C (en) 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
ITTO20060852A1 (it) * 2006-11-30 2008-06-01 Univ Degli Studi Torino Peptidi metastasi-specifici e loro applicazioni diagnostiche e terapeutiche
US8722851B2 (en) 2007-11-02 2014-05-13 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
JP2009126811A (ja) * 2007-11-22 2009-06-11 Kyoto Univ 合成ペプチド及びその利用
KR20110084280A (ko) 2008-11-03 2011-07-21 알레시아 바이오쎄라퓨틱스 인코포레이티드 종양 항원의 생물 활성을 특이적으로 차단하는 항체
GB0823366D0 (en) 2008-12-22 2009-01-28 Uni I Oslo Synthesis
FR2961814B1 (fr) * 2010-06-29 2014-09-26 Isp Investments Inc Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
US20120055055A1 (en) 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
EP2444101A1 (en) * 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
WO2012118547A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
RS59080B1 (sr) 2011-03-31 2019-09-30 Adc Therapeutics Sa Antitela protiv antigena 1 povezanog sa bubrezima i njihovi fragmenti koji se vezuju za antigen
WO2012170975A1 (en) * 2011-06-10 2012-12-13 The United States Of America As Representrd By The Secretary Of The Navy Nano-encapsulated therapeutics for controlled treatment of infection and other diseases
CN103764668B (zh) * 2011-07-09 2016-08-17 加利福尼亚大学董事会 白血病干细胞靶向配体及应用方法
EP2756002A4 (en) * 2011-09-16 2015-04-08 Univ Texas COMPOSITIONS AND METHODS RELATED TO THE REPAIR OF DNA DAMAGES
HRP20190946T1 (hr) 2012-01-09 2019-07-26 Adc Therapeutics Sa Sredstva za liječenje trostruko negativnog raka dojke
AU2013248301B2 (en) * 2012-04-16 2017-11-09 Lubrizol Advanced Materials, Inc. Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions
CN103387603B (zh) * 2012-05-08 2015-07-15 复旦大学 一种rtn4b相关多肽及其制备与应用
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
EP3456734B1 (en) 2012-10-04 2022-01-05 Research Development Foundation Serine protease molecules and therapies
US9267114B2 (en) 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly
KR20160068738A (ko) 2013-08-14 2016-06-15 윌리엄 마쉬 라이스 유니버시티 운시알라마이신의 유도체, 합성 방법 및 항종양 제제로서 이들의 용도
CN105828841A (zh) 2013-11-04 2016-08-03 辉瑞大药厂 抗-efna4抗体-药物缀合物
CN103804470B (zh) * 2014-01-22 2016-08-17 深圳市奥尼克斯基因技术有限公司 一种特异性靶向肿瘤淋巴管的新型多肽tmvp1的获得及应用
AU2016298210B2 (en) 2015-07-28 2021-12-09 Board Of Regents, The University Of Texas System Implant compositions for the unidirectional delivery of therapeutic compounds to the brain
WO2017057450A1 (ja) * 2015-10-01 2017-04-06 国立大学法人新潟大学 胆道癌に特異的な集積性を有するペプチド及びその使用
CA3014921A1 (en) 2016-02-16 2017-08-24 Research Development Foundation Sortase-modified molecules and uses thereof
EP3548097A4 (en) 2016-12-02 2020-07-01 Avelas Biosciences, Inc. NERVE MARKING COMPOSITIONS AND USES THEREOF
CN118652192A (zh) 2017-05-24 2024-09-17 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372473B1 (en) * 1997-05-28 2002-04-16 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
EP1315512A4 (en) 2000-09-08 2005-11-09 Univ Texas TARGETED INTRODUCTION USING ADENOVIRES AND ADENOVIRAL MANIPULATION IMMUNES SYSTEM RESPONSE USING TARGETED PEPTIDES
US20030143539A1 (en) 2000-12-08 2003-07-31 Francois Bertucci Gene expression profiling of primary breast carcinomas using arrays of candidate genes
US20040048243A1 (en) 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
WO2003086289A2 (en) * 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
EP1369482A1 (en) 2002-06-07 2003-12-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Target genes for the diagnosis and treatment of cancer
WO2005070966A2 (en) * 2004-01-16 2005-08-04 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
TW200600784A (en) * 2004-06-02 2006-01-01 Sidney Kimmel Cancer Ct Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
WO2006010070A2 (en) * 2004-07-10 2006-01-26 Board Of Regents, The University Of Texas System Compositions and methods related to peptides that selectively bind leukemia cells
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY

Also Published As

Publication number Publication date
AU2007222991A2 (en) 2009-03-12
JP2009529333A (ja) 2009-08-20
WO2007104062A3 (en) 2008-11-27
US20070248952A1 (en) 2007-10-25
US7781565B2 (en) 2010-08-24
CA2645277A1 (en) 2007-09-13
US20100298233A1 (en) 2010-11-25
AU2007222991A8 (en) 2011-03-10
EP2002036A2 (en) 2008-12-17
WO2007104062A8 (en) 2008-10-09
US20130089498A1 (en) 2013-04-11
WO2007104062A2 (en) 2007-09-13
JP5167155B2 (ja) 2013-03-21
EP2338898A1 (en) 2011-06-29
EP2002036A4 (en) 2010-01-27

Similar Documents

Publication Publication Date Title
US7781565B2 (en) Compositions and methods related to profiling a plurality of cells based on peptide binding
Kolonin et al. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries
US11768201B1 (en) Methods of assaying proteins
US11970693B2 (en) Methods of selecting binding reagents
Rockberg et al. Epitope mapping of antibodies using bacterial surface display
US8163567B2 (en) Methods and compositions comprising capture agents
Shukla et al. Phage display selection for cell-specific ligands: development of a screening procedure suitable for small tumor specimens
Zhang et al. Screening and selection of peptides specific for esophageal cancer cells from a phage display peptide library
Nobrega et al. Screening and characterization of novel specific peptides targeting MDA-MB-231 claudin-low breast carcinoma by computer-aided phage display methodologies
Helmer et al. Peptides and peptide analogs to inhibit protein-protein interactions
Doran et al. A liquid array platform for the multiplexed analysis of synthetic molecule–protein interactions
Konthur et al. High-throughput applications of phage display in proteomic analyses
Kodadek Synthetic receptors with antibody-like binding affinities
Casado-Vela et al. Protein arrays: recent achievements and their application to study the human proteome
Ballard et al. Quantitative PCR-based approach for rapid phage display analysis: a foundation for high throughput vascular proteomic profiling
Staquicini et al. Combinatorial vascular targeting in translational medicine
Park et al. Phage display screen for peptides that bind Bcl-2 protein
Ben Abid et al. New Phage Display-Isolated Heptapeptide Recognizing the Regulatory Carboxy-Terminal Domain of Human Tumour Protein p53
Hung et al. Phage display for imaging agent development
Kim et al. In Situ Click Chemistry Screen Facilitated by an On‐Nanoparticle DNA‐Encoded Library Identifies Highly Selective and Potent Peptoid Ligands for a Phosphatase
Bi et al. Detection of breast cancer-related antigens through cDNA phage-displayed protein microarray.
Hu Coupling Synthetic Antibodies with Mass Cytometry Allows the Development of a Highly Tailored, Multi-Parametric Single Cell Analysis Strategy
Cho et al. Use of the Phage Display Technique to Identify the Target Protein
Koide et al. c12) United States Patent

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 03 FEB 2009

TH Corrigenda

Free format text: IN VOL 22, NO 44, PAGE(S) 5212 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS, APPLICATION NO. 2007222991, UNDER INID (54) CORRECT THE TITLE TO COMPOSITIONS AND METHODS BASED ON PEPTIDE BINDING PROFILING

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application